Skip To Main Content
Campus
  • Utbildning
Campus
  • Utbildning
View Full Results

Artiklar

Sort by

Filtrera

Återställ
  • Filtera
Approach for patients with coronary artery disease (CAD): focus on LDL-C control

Approach for patients with coronary artery disease (CAD): focus on LDL-C control

Läs mer
Approach for patients with peripheral artery disease (PAD) + T2DM: focus on LDL-C control

Approach for patients with peripheral artery disease (PAD) + T2DM: focus on LDL-C control

Läs mer
Cardiovascular diseases (CVDs) are the leading cause of death globally<sup>1</sup>

Cardiovascular diseases (CVDs) are the leading cause of death globally

Läs mer
PRALUENT is available as a unique,<sup>¥</sup> once-monthly pen

PRALUENT is available as a unique,¥ once-monthly pen

Läs mer
Why choose PRALUENT<sup>®</sup>?

Why choose PRALUENT®?

The usual starting dose for PRALUENT is 75 mg administered subcutaneously once every 2 weeks. Patients requiring larger LDL-C reduction (>60%) may be started on 150 mg once every 2 weeks, or 300 mg once every 4 weeks (monthly), administered subcutaneously.2

Läs mer
What is PRALUENT<sup>®</sup>(alirocumab)?

What is PRALUENT®(alirocumab)?

PRALUENT®: a PCSK9i that ticks all the boxes1–4

 

PRALUENT is a PCSK9i that reduces the levels of LDL-C in the blood.2 It is a fully human IgG1 monoclonal antibody that works by inhibiting the binding of PCSK9 to LDL- receptors. As a result, PRALUENT increases the number of LDL-receptors available to clear LDL, thereby lowering LDL-C levels.2 Elevated LDL-C levels have been significantly associated with cardiovascular disease such as heart attacks and strokes.1

Läs mer
How Does Glycaemic Control Impact Complications in Type 2 Diabetes?

How Does Glycaemic Control Impact Complications in Type 2 Diabetes?

Summary of The UK Prospective Diabetes Study (UKPDS).

Läs mer
Why is Glycaemic Control in Type 2 Diabetes Still a Challenge?

Why is Glycaemic Control in Type 2 Diabetes Still a Challenge?

Summary of Aschner P, et al. Diabetologia. 2020;63(4):711-721.

Läs mer
Is Glycemic Control the Key to Preventing Long-term Complications in Type 2 Diabetes?

Is Glycemic Control the Key to Preventing Long-term Complications in Type 2 Diabetes?

(Based on the study: Stratton IM, et al. BMJ. 2000;321(7258):405-12).

Läs mer
The Complex Burden of Autoimmune Type 1 Diabetes

The Complex Burden of Autoimmune Type 1 Diabetes

Läs mer
Uncovering the Hidden Burden: Understanding Loss of Smell in CRSwNP

Uncovering the Hidden Burden: Understanding Loss of Smell in CRSwNP

Navigating the Complexities of Smell Loss in Patients with CRSwNP.

Läs mer
The Long-Term Impact of Early-Onset Atopic Dermatitis

The Long-Term Impact of Early-Onset Atopic Dermatitis

A recent study led by professor Jonathan Silverberg involving over 30,000 participants has highlighted the significant psychosocial burden faced by adults with early-onset atopic dermatitis (AD). Learn more and continue reading.

Läs mer